RCT | Tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced esophageal squamous cell carcinoma

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

NOW OF: Interim analysis of the RATIONALE-306 trial of 1st-line tislelizumab + chemo vs placebo + chemo in adv or metastatic oesophageal squamous cell carcinoma—median OS 17·2 mo (95% CI 15·8–20·1) vs 10·6 mo (9·3–12·1; HR 0·66, 95% CI 0·54–0·80; p<0·0001)https://t.co/25lyg2Ef0o pic.twitter.com/vizCPVd8bj

— The Lancet Oncology (@TheLancetOncol) April 18, 2023